{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:34:33Z","timestamp":1791488073962,"version":"4.3.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T00:00:00Z","timestamp":1670025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T00:00:00Z","timestamp":1670025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100013996","name":"Global Health Innovative Technology Fund","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013996","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Leishmaniasis is one of the top neglected tropical diseases with significant morbidity and mortality in low and middle-income countries (LMIC). However, this disease is also spreading in the developed world. Currently, there is a lack of effective strategies to control this disease. Vaccination can be an effective measure to control leishmaniasis and has the potential to achieve disease elimination. Recently, we have generated<jats:italic>centrin<\/jats:italic>gene-deleted new world<jats:italic>L. mexicana<\/jats:italic>(<jats:italic>LmexCen<\/jats:italic><jats:sup><jats:italic>\u2212\/\u2212<\/jats:italic><\/jats:sup>) parasites using CRISPR\/Cas9 and showed that they protect mice against a homologous<jats:italic>L. mexicana<\/jats:italic>infection that causes cutaneous disease. In this study, we tested whether<jats:italic>LmexCen<\/jats:italic><jats:sup><jats:italic>\u2212\/\u2212<\/jats:italic><\/jats:sup>parasites can also protect against visceral leishmaniasis caused by<jats:italic>L. donovani<\/jats:italic>in a hamster model. We showed that immunization with<jats:italic>LmexCen<\/jats:italic><jats:sup><jats:italic>\u2212\/\u2212<\/jats:italic><\/jats:sup>parasites is safe and does not cause lesions. Furthermore, such immunization conferred protection against visceral leishmaniasis caused by a needle-initiated<jats:italic>L. donovani<\/jats:italic>challenge, as indicated by a significant reduction in the parasite burdens in the spleen and liver as well as reduced mortality. Similar control of parasite burden was also observed against a sand fly mediated<jats:italic>L. donovani<\/jats:italic>challenge. Importantly, immunization with<jats:italic>LmexCen<\/jats:italic><jats:sup><jats:italic>\u2212\/\u2212<\/jats:italic><\/jats:sup>down-regulated the disease promoting cytokines IL-10 and IL-4 and increased pro-inflammatory cytokine IFN-\u03b3 resulting in higher IFN-\u03b3\/IL-10 and IFN-\u03b3\/IL4 ratios compared to non-immunized animals.<jats:italic>LmexCen<\/jats:italic><jats:sup><jats:italic>\u2212\/\u2212<\/jats:italic><\/jats:sup>immunization also resulted in long-lasting protection against<jats:italic>L. donovani<\/jats:italic>infection. Taken together, our study demonstrates that immunization with<jats:italic>LmexCen<\/jats:italic><jats:sup><jats:italic>\u2212\/\u2212<\/jats:italic><\/jats:sup>parasites is safe and efficacious against the Old World visceral leishmaniasis.<\/jats:p>","DOI":"10.1038\/s41541-022-00574-x","type":"journal-article","created":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T10:02:50Z","timestamp":1670061770000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Centrin-deficient Leishmania mexicana confers protection against Old World visceral leishmaniasis"],"prefix":"10.1038","volume":"7","author":[{"given":"Subir","family":"Karmakar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greta","family":"Volpedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1996-876X","authenticated-orcid":false,"given":"Wen-Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5550-712X","authenticated-orcid":false,"given":"Patrick","family":"Lypaczewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0294-8834","authenticated-orcid":false,"given":"Nevien","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7924-8038","authenticated-orcid":false,"given":"Fabiano","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Oristian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Meneses","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6557-8220","authenticated-orcid":false,"given":"Sreenivas","family":"Gannavaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4304-636X","authenticated-orcid":false,"given":"Shaden","family":"Kamhawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3881-8337","authenticated-orcid":false,"given":"Shinjiro","family":"Hamano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5589-9450","authenticated-orcid":false,"given":"Jesus G.","family":"Valenzuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8971-5525","authenticated-orcid":false,"given":"Greg","family":"Matlashewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5989-1520","authenticated-orcid":false,"given":"Abhay R.","family":"Satoskar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0069-7867","authenticated-orcid":false,"given":"Ranadhir","family":"Dey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4941-1620","authenticated-orcid":false,"given":"Hira L.","family":"Nakhasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,3]]},"reference":[{"key":"574_CR1","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(18)31204-2","volume":"392","author":"S Burza","year":"2018","unstructured":"Burza, S., Croft, S. L. & Boelaert, M. Leishmaniasis. Lancet 392, 951\u2013970 (2018).","journal-title":"Lancet"},{"key":"574_CR2","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/nrmicro2608","volume":"9","author":"P Kaye","year":"2011","unstructured":"Kaye, P. & Scott, P. Leishmaniasis: complexity at the host-pathogen interface. Nat. Rev. Microbiol 9, 604\u2013615 (2011).","journal-title":"Nat. Rev. Microbiol"},{"key":"574_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/qjmed\/hct116","volume":"107","author":"BS McGwire","year":"2014","unstructured":"McGwire, B. S. & Satoskar, A. R. Leishmaniasis: clinical syndromes and treatment. QJM 107, 7\u201314 (2014).","journal-title":"QJM"},{"key":"574_CR4","doi-asserted-by":"publisher","unstructured":"Curtin, J. M. & Aronson, N. E. Leishmaniasis in the United States: emerging issues in a region of low endemicity. Microorganisms 9, https:\/\/doi.org\/10.3390\/microorganisms9030578 (2021).","DOI":"10.3390\/microorganisms9030578"},{"key":"574_CR5","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1001\/jamadermatol.2018.2133","volume":"154","author":"BE McIlwee","year":"2018","unstructured":"McIlwee, B. E., Weis, S. E. & Hosler, G. A. Incidence of endemic human cutaneous leishmaniasis in the United States. JAMA Dermatol. 154, 1032\u20131039 (2018).","journal-title":"JAMA Dermatol."},{"key":"574_CR6","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1017\/S003118201600216X","volume":"145","author":"Y Taslimi","year":"2018","unstructured":"Taslimi, Y., Zahedifard, F. & Rafati, S. Leishmaniasis and various immunotherapeutic approaches. Parasitology 145, 497\u2013507 (2018).","journal-title":"Parasitology"},{"key":"574_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2147\/DDDT.S146521","volume":"12","author":"M Ghorbani","year":"2018","unstructured":"Ghorbani, M. & Farhoudi, R. Leishmaniasis in humans: drug or vaccine therapy. Drug Des. Devel Ther. 12, 25\u201340 (2018).","journal-title":"Drug Des. Devel Ther."},{"key":"574_CR8","doi-asserted-by":"publisher","first-page":"e0006052","DOI":"10.1371\/journal.pntd.0006052","volume":"11","author":"A Ponte-Sucre","year":"2017","unstructured":"Ponte-Sucre, A. et al. Drug resistance and treatment failure in leishmaniasis: a 21st century challenge. PLoS Negl. Trop. Dis. 11, e0006052 (2017).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"574_CR9","first-page":"29","volume":"80","author":"R Lainson","year":"1977","unstructured":"Lainson, R. & Shaw, J. J. Leishmaniasis in Brazil: XII. Observations on cross-immunity in monkeys and man infected with Leishmania mexicana mexicana, L. m. amazonensis, L. braziliensis braziliensis, L. b. guyanensis and L. b. panamensis. J. Trop. Med. Hyg. 80, 29\u201335 (1977).","journal-title":"J. Trop. Med. Hyg."},{"key":"574_CR10","doi-asserted-by":"publisher","first-page":"297","DOI":"10.4269\/ajtmh.2004.71.297","volume":"71","author":"R Porrozzi","year":"2004","unstructured":"Porrozzi, R., Teva, A., Amaral, V. F., Santos da Costa, M. V. & Grimaldi, G. Jr. Cross-immunity experiments between different species or strains of Leishmania in rhesus macaques (Macaca mulatta). Am. J. Trop. Med Hyg. 71, 297\u2013305 (2004).","journal-title":"Am. J. Trop. Med Hyg."},{"key":"574_CR11","doi-asserted-by":"publisher","first-page":"e1284","DOI":"10.1371\/journal.pntd.0001284","volume":"5","author":"B Ostyn","year":"2011","unstructured":"Ostyn, B. et al. Incidence of symptomatic and asymptomatic Leishmania donovani infections in high-endemic foci in India and Nepal: a prospective study. PLoS Negl. Trop. Dis. 5, e1284 (2011).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"574_CR12","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1086\/313697","volume":"30","author":"SM Jeronimo","year":"2000","unstructured":"Jeronimo, S. M. et al. Natural history of Leishmania (Leishmania) chagasi infection in Northeastern Brazil: long-term follow-up. Clin. Infect. Dis. 30, 608\u2013609 (2000).","journal-title":"Clin. Infect. Dis."},{"key":"574_CR13","first-page":"377","volume":"76","author":"A Nadim","year":"1983","unstructured":"Nadim, A., Javadian, E., Tahvildar-Bidruni, G. & Ghorbani, M. Effectiveness of leishmanization in the control of cutaneous leishmaniasis. Bull. Soc. Pathol. Exot. Filiales 76, 377\u2013383 (1983).","journal-title":"Bull. Soc. Pathol. Exot. Filiales"},{"key":"574_CR14","first-page":"306","volume":"74","author":"OI Kellina","year":"1981","unstructured":"Kellina, O. I. Problem and current lines in investigations on the epidemiology of leishmaniasis and its control in the U.S.S.R. Bull. Soc. Pathol. Exot. Filiales 74, 306\u2013318 (1981).","journal-title":"Bull. Soc. Pathol. Exot. Filiales"},{"key":"574_CR15","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.3389\/fimmu.2018.01227","volume":"9","author":"N Seyed","year":"2018","unstructured":"Seyed, N., Peters, N. C. & Rafati, S. Translating observations from leishmanization into non-living vaccines: the potential of dendritic cell-based vaccination strategies against leishmania. Front. Immunol. 9, 1227 (2018).","journal-title":"Front. Immunol."},{"key":"574_CR16","doi-asserted-by":"publisher","first-page":"3816","DOI":"10.4049\/jimmunol.1500752","volume":"195","author":"A Romano","year":"2015","unstructured":"Romano, A., Doria, N. A., Mendez, J., Sacks, D. L. & Peters, N. C. Cutaneous infection with Leishmania major mediates heterologous protection against visceral infection with Leishmania infantum. J. Immunol. 195, 3816\u20133827 (2015).","journal-title":"J. Immunol."},{"key":"574_CR17","doi-asserted-by":"publisher","first-page":"826","DOI":"10.4269\/ajtmh.1994.51.826","volume":"51","author":"EE Zijlstra","year":"1994","unstructured":"Zijlstra, E. E., el-Hassan, A. M., Ismael, A. & Ghalib, H. W. Endemic kala-azar in eastern Sudan: a longitudinal study on the incidence of clinical and subclinical infection and post-kala-azar dermal leishmaniasis. Am. J. Trop. Med Hyg. 51, 826\u2013836 (1994).","journal-title":"Am. J. Trop. Med Hyg."},{"key":"574_CR18","doi-asserted-by":"publisher","first-page":"291","DOI":"10.4161\/hv.5.5.7607","volume":"5","author":"I Okwor","year":"2009","unstructured":"Okwor, I. & Uzonna, J. Vaccines and vaccination strategies against human cutaneous leishmaniasis. Hum. Vaccin 5, 291\u2013301 (2009).","journal-title":"Hum. Vaccin"},{"key":"574_CR19","doi-asserted-by":"publisher","first-page":"6759","DOI":"10.1016\/j.vaccine.2008.09.085","volume":"26","author":"S Noazin","year":"2008","unstructured":"Noazin, S. et al. First generation leishmaniasis vaccines: a review of field efficacy trials. Vaccine 26, 6759\u20136767 (2008).","journal-title":"Vaccine"},{"key":"574_CR20","doi-asserted-by":"publisher","unstructured":"Scorza, B. M., Carvalho, E. M. & Wilson, M. E. Cutaneous manifestations of human and murine leishmaniasis. Int J Mol Sci. 18, https:\/\/doi.org\/10.3390\/ijms18061296 (2017).","DOI":"10.3390\/ijms18061296"},{"key":"574_CR21","doi-asserted-by":"publisher","first-page":"2603730","DOI":"10.1155\/2019\/2603730","volume":"2019","author":"A Gabriel","year":"2019","unstructured":"Gabriel, A. et al. Cutaneous leishmaniasis: the complexity of host\u2019s effective immune response against a polymorphic parasitic disease. J. Immunol. Res 2019, 2603730 (2019).","journal-title":"J. Immunol. Res"},{"key":"574_CR22","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1093\/intimm\/dxh313","volume":"17","author":"LE Rosas","year":"2005","unstructured":"Rosas, L. E. et al. Genetic background influences immune responses and disease outcome of cutaneous L. mexicana infection in mice. Int Immunol. 17, 1347\u20131357 (2005).","journal-title":"Int Immunol."},{"key":"574_CR23","doi-asserted-by":"publisher","first-page":"656919","DOI":"10.3389\/fimmu.2021.656919","volume":"12","author":"MB Paiva","year":"2021","unstructured":"Paiva, M. B. et al. A cytokine network balance influences the fate of Leishmania (Viannia) braziliensis infection in a cutaneous leishmaniasis hamster model. Front Immunol. 12, 656919 (2021).","journal-title":"Front Immunol."},{"key":"574_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00449-1","volume":"7","author":"G Volpedo","year":"2022","unstructured":"Volpedo, G. et al. Centrin-deficient Leishmania mexicana confers protection against New World cutaneous leishmaniasis. NPJ Vaccin. 7, 32 (2022).","journal-title":"NPJ Vaccin."},{"key":"574_CR25","doi-asserted-by":"publisher","first-page":"25703","DOI":"10.1074\/jbc.M402794200","volume":"279","author":"A Selvapandiyan","year":"2004","unstructured":"Selvapandiyan, A. et al. Centrin gene disruption impairs stage-specific basal body duplication and cell cycle progression in Leishmania. J. Biol. Chem. 279, 25703\u201325710 (2004).","journal-title":"J. Biol. Chem."},{"key":"574_CR26","doi-asserted-by":"publisher","first-page":"3290","DOI":"10.1091\/mbc.e07-01-0022","volume":"18","author":"A Selvapandiyan","year":"2007","unstructured":"Selvapandiyan, A. et al. Centrin1 is required for organelle segregation and cytokinesis in Trypanosoma brucei. Mol. Biol. Cell 18, 3290\u20133301 (2007).","journal-title":"Mol. Biol. Cell"},{"key":"574_CR27","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/s42003-021-02446-x","volume":"4","author":"S Karmakar","year":"2021","unstructured":"Karmakar, S. et al. Preclinical validation of a live attenuated dermotropic Leishmania vaccine against vector transmitted fatal visceral leishmaniasis. Commun. Biol. 4, 929 (2021).","journal-title":"Commun. Biol."},{"key":"574_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17154-z","volume":"11","author":"WW Zhang","year":"2020","unstructured":"Zhang, W. W. et al. A second generation leishmanization vaccine with a markerless attenuated Leishmania major strain using CRISPR gene editing. Nat. Commun. 11, 3461 (2020).","journal-title":"Nat. Commun."},{"key":"574_CR29","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1093\/infdis\/jis932","volume":"207","author":"H Aslan","year":"2013","unstructured":"Aslan, H. et al. A new model of progressive visceral leishmaniasis in hamsters by natural transmission via bites of vector sand flies. J. Infect. Dis. 207, 1328\u20131338 (2013).","journal-title":"J. Infect. Dis."},{"key":"574_CR30","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.4049\/jimmunol.1303145","volume":"193","author":"R Dey","year":"2014","unstructured":"Dey, R. et al. Characterization of cross-protection by genetically modified live-attenuated Leishmania donovani parasites against Leishmania mexicana. J. Immunol. 193, 3513\u20133527 (2014).","journal-title":"J. Immunol."},{"key":"574_CR31","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/ni725","volume":"2","author":"T Biedermann","year":"2001","unstructured":"Biedermann, T. et al. IL-4 instructs TH1 responses and resistance to Leishmania major in susceptible BALB\/c mice. Nat. Immunol. 2, 1054\u20131060 (2001).","journal-title":"Nat. Immunol."},{"key":"574_CR32","doi-asserted-by":"publisher","first-page":"e1003699","DOI":"10.1371\/journal.ppat.1003699","volume":"9","author":"R Hurdayal","year":"2013","unstructured":"Hurdayal, R. et al. Deletion of IL-4 receptor alpha on dendritic cells renders BALB\/c mice hypersusceptible to Leishmania major infection. PLoS Pathog. 9, e1003699 (2013).","journal-title":"PLoS Pathog."},{"key":"574_CR33","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/0014-4894(79)90079-1","volume":"47","author":"HR Wilson","year":"1979","unstructured":"Wilson, H. R., Dieckmann, B. S. & Childs, G. E. Leishmania braziliensis and Leishmania mexicana: experimental cutaneous infections in golden hamsters. Exp. Parasitol. 47, 270\u2013283 (1979).","journal-title":"Exp. Parasitol."},{"key":"574_CR34","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.4049\/jimmunol.166.3.1912","volume":"166","author":"PC Melby","year":"2001","unstructured":"Melby, P. C., Chandrasekar, B., Zhao, W. & Coe, J. E. The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response. J. Immunol. 166, 1912\u20131920 (2001).","journal-title":"J. Immunol."},{"key":"574_CR35","doi-asserted-by":"crossref","first-page":"5949","DOI":"10.4049\/jimmunol.152.12.5949","volume":"152","author":"EM Carvalho","year":"1994","unstructured":"Carvalho, E. M. et al. Restoration of IFN-gamma production and lymphocyte proliferation in visceral leishmaniasis. J. Immunol. 152, 5949\u20135956 (1994).","journal-title":"J. Immunol."},{"key":"574_CR36","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1172\/JCI116372","volume":"91","author":"CL Karp","year":"1993","unstructured":"Karp, C. L. et al. In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma. J. Clin. Invest 91, 1644\u20131648 (1993).","journal-title":"J. Clin. Invest"},{"key":"574_CR37","doi-asserted-by":"publisher","first-page":"546","DOI":"10.4049\/immunohorizons.2000076","volume":"4","author":"B Poudel","year":"2020","unstructured":"Poudel, B. et al. Acute IL-4 governs pathogenic T cell responses during Leishmania major Infection. Immunohorizons 4, 546\u2013560 (2020).","journal-title":"Immunohorizons"},{"key":"574_CR38","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.4049\/jimmunol.171.7.3705","volume":"171","author":"UM Padigel","year":"2003","unstructured":"Padigel, U. M., Alexander, J. & Farrell, J. P. The role of interleukin-10 in susceptibility of BALB\/c mice to infection with Leishmania mexicana and Leishmania amazonensis. J. Immunol. 171, 3705\u20133710 (2003).","journal-title":"J. Immunol."},{"key":"574_CR39","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1002\/1521-4141(2002010)32:10<2923::AID-IMMU2923>3.0.CO;2-E","volume":"32","author":"J Alexander","year":"2002","unstructured":"Alexander, J. et al. An essential role for IL-13 in maintaining a non-healing response following Leishmania mexicana infection. Eur. J. Immunol. 32, 2923\u20132933 (2002).","journal-title":"Eur. J. Immunol."},{"key":"574_CR40","doi-asserted-by":"publisher","first-page":"e930","DOI":"10.1371\/journal.pntd.0000930","volume":"5","author":"KJ Bryson","year":"2011","unstructured":"Bryson, K. J. et al. BALB\/c mice deficient in CD4 T cell IL-4Ralpha expression control Leishmania mexicana Load although female but not male mice develop a healer phenotype. PLoS Negl. Trop. Dis. 5, e930 (2011).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"574_CR41","doi-asserted-by":"publisher","first-page":"4894","DOI":"10.1128\/iai.63.12.4894-4899.1995","volume":"63","author":"A Satoskar","year":"1995","unstructured":"Satoskar, A., Bluethmann, H. & Alexander, J. Disruption of the murine interleukin-4 gene inhibits disease progression during Leishmania mexicana infection but does not increase control of Leishmania donovani infection. Infect. Immun. 63, 4894\u20134899 (1995).","journal-title":"Infect. Immun."},{"key":"574_CR42","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1080\/14760584.2021.1991795","volume":"20","author":"V Parkash","year":"2021","unstructured":"Parkash, V., Kaye, P. M., Layton, A. M. & Lacey, C. J. Vaccines against leishmaniasis: using controlled human infection models to accelerate development. Expert Rev. Vaccin. 20, 1407\u20131418 (2021).","journal-title":"Expert Rev. Vaccin."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00574-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00574-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00574-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T18:02:24Z","timestamp":1678903344000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00574-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,3]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["574"],"URL":"https:\/\/doi.org\/10.1038\/s41541-022-00574-x","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,3]]},"assertion":[{"value":"1 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The FDA is currently a co-owner of two US patents that claim attenuated <i>Leishmania<\/i> species with the <i>centrin<\/i> gene deletion (US7,887,812 and US 8,877,213). All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"157"}}